Full Name
Marie-Charlotte Delignette
Job Title
Anesthesiologist and Intensivist
Company/Institution/ Organization
Hospices Civils de Lyon
Speaker Bio
Dr. Marie-Charlotte Delignette is an anesthesiologist and intensivist, and Head of the Surgical Intensive Care Unit at Hôpital de la Croix-Rousse, Hospices Civils de Lyon, France. Her unit specializes in the perioperative management of liver transplant recipients and critically ill patients with liver failure, combining clinical expertise in hepatic intensive care and anesthesia for liver transplantation.
She is a member of the PathLIv research team within IHU EVEREST (intEgratiVE RESearch in hepaTology), the first and only state-labelled Institut Hospitalo-Universitaire entirely dedicated to hepatic diseases, supported by the Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Inserm, and Centre Léon Bérard. Her research focuses on immune dysregulation in critically ill patients, encompassing cirrhosis, liver failure, and the post-transplant setting. She recently completed a PhD thesis on perioperative immune dysfunction following liver transplantation and its impact on post-transplant outcomes. Her broader clinical research interests include infectious complications in acute liver disease and hemodynamic management
Dr. Delignette is an active member of the Research Network Committee of the Société Française d'Anesthésie et de Réanimation (SFAR) and of the social media team of Anaesthesia Critical Care & Pain Medicine (ACCPM). She also contributes to academic teaching as faculty in a university diploma in hemodynamic ultrasound monitoring in intensive care.
At this congress, she presents a prospective ancillary study of the EDMONHG cohort investigating whether pre-transplant and early post-transplant inflammatory biomarkers — neutrophil-to-lymphocyte ratio (NLR), interleukin-6 (IL-6), and nucleosomes — predict infection and one-year survival after liver transplantation.
She is a member of the PathLIv research team within IHU EVEREST (intEgratiVE RESearch in hepaTology), the first and only state-labelled Institut Hospitalo-Universitaire entirely dedicated to hepatic diseases, supported by the Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Inserm, and Centre Léon Bérard. Her research focuses on immune dysregulation in critically ill patients, encompassing cirrhosis, liver failure, and the post-transplant setting. She recently completed a PhD thesis on perioperative immune dysfunction following liver transplantation and its impact on post-transplant outcomes. Her broader clinical research interests include infectious complications in acute liver disease and hemodynamic management
Dr. Delignette is an active member of the Research Network Committee of the Société Française d'Anesthésie et de Réanimation (SFAR) and of the social media team of Anaesthesia Critical Care & Pain Medicine (ACCPM). She also contributes to academic teaching as faculty in a university diploma in hemodynamic ultrasound monitoring in intensive care.
At this congress, she presents a prospective ancillary study of the EDMONHG cohort investigating whether pre-transplant and early post-transplant inflammatory biomarkers — neutrophil-to-lymphocyte ratio (NLR), interleukin-6 (IL-6), and nucleosomes — predict infection and one-year survival after liver transplantation.
Speaking At
